Purpose: To report changing in intraocular pressures (IOP) after intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to age-releated macular degeneration and to assess its safety.

Materials and Methods: The study included 95 intravitreal injections of 88 eyes of 69 patients who received intravitreal injections of 0.05 ml (0.5 mg) ranibizumab. The effect of intravitreal injections of ranibizumab on IOP was performed. IOP was measured 2, 45, 120 minutes, 24 hours, 1 week and 4 weeks after injection.

Results: The mean preinjection IOP was 15.70±3.71 mmHg (mean±SD) (range, 13 to 20 mmHg). The mean postinjection IOP 2, 45, 120 minutes after injection was 40.64±7.43 mmHg (range, 12 to 60 mmHg), 28±6.80 mmHg (range, 13 to 38 mmHg), 19. 10±4.18 mmHg (range, 14 to 30 mmHg), respectively. The mean postinjection IOP 24 hours after injection was 16.04±4.43 mmHg (range, 12 to 24 mmHg). At 1-week follow-up, the average IOP was 15.98±3.02 mmHg (range, 14 to 21 mmHg). At 4-week follow-up, the average IOP was 15.86±2.88 mmHg (range, 14 to 20 mmHg).

Conclusions: Our study shows that 0.05 ml (0.5 mg) ranibizumab intravitreal injections cause transient IOP elevation with in immediately after injection but does not cause a marked increase in IOP at the 120 minutes after the procedure. Ranibizumab injection is safe in terms of elevation of IOP.